Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2016

General framework for meta-analysis of haplotype association
tests
Ping An
Washington University School of Medicine in St. Louis

Ingrid B. Borecki
Washington University School of Medicine in St. Louis

Michael A. Province
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
An, Ping; Borecki, Ingrid B.; Province, Michael A.; and et al, ,"General framework for meta-analysis of
haplotype association tests." Genetic Epidemiology. 40,3. 244-252. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5497

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Genetic
Epidemiology

RESEARCH ARTICLE
General Framework for Meta-Analysis of Haplotype
Association Tests

Shuai Wang,1 Jing Hua Zhao,2 Ping An,3 Xiuqing Guo,4 Richard A. Jensen,5,6 Jonathan Marten,7 Jennifer E. Huffman,7
Karina Meidtner,8 Heiner Boeing,9 Archie Campbell,10 Kenneth M. Rice,11 Robert A. Scott,2 Jie Yao,4
Matthias B. Schulze,8,12 Nicholas J. Wareham,2 Ingrid B. Borecki,3 Michael A. Province,3 Jerome I. Rotter,4
Caroline Hayward,6,10 Mark O. Goodarzi,13 James B. Meigs,14,15 and Josée Dupuis1,16 ∗
1

Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America; 2 MRC Epidemiology
Unit, School of Clinical Medicine, University of Cambridge, Box 285 Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge,
United Kingdom; 3 Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, United
States of America; 4 Department of Pediatrics, The Institute for Translational Genomics and Population Sciences, LABioMed at Harbor-UCLA
Medical Center, Torrance, California, United States of America; 5 Cardiovascular Health Research Unit, University of Washington, Seattle,
Washington, United States of America; 6 Department of Medicine, University of Washington, Seattle, Washington, United States of America; 7 MRC
Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, United Kingdom; 8 Department of Molecular Epidemiology, German Institute
of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; 9 Department of Epidemiology, German Institute of Human Nutrition
Potsdam-Rehbruecke, Nuthetal, Germany; 10 Generation Scotland, Centre for Genomic and Experimental Medicine, Institute of Genetic and
Molecular Medicine, Western General Hospital, University of Edinburgh, Edinburgh, United Kindom; 11 Department of Biostatistics, University of
Washington, Seattle, Washington, United States of America; 12 German Center for Diabetes Research (DZD), Germany; 13 Division of
Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, California, United States of America; 14 General Medicine
Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America; 15 Department of Medicine, Harvard Medical
School, Boston, Massachusetts, United States of America; 16 National Heart, Lung, Blood Institute (NHLBI), Framingham Heart Study, Framingham,
Massachusetts, United States of America
Received 23 July 2015; Revised 3 November 2015; accepted revised manuscript 14 December 2015.
Published online 8 March 2016 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/gepi.21959

ABSTRACT: For complex traits, most associated single nucleotide variants (SNV) discovered to date have a small effect, and
detection of association is only possible with large sample sizes. Because of patient confidentiality concerns, it is often not
possible to pool genetic data from multiple cohorts, and meta-analysis has emerged as the method of choice to combine results
from multiple studies. Many meta-analysis methods are available for single SNV analyses. As new approaches allow the capture
of low frequency and rare genetic variation, it is of interest to jointly consider multiple variants to improve power. However,
for the analysis of haplotypes formed by multiple SNVs, meta-analysis remains a challenge, because different haplotypes
may be observed across studies. We propose a two-stage meta-analysis approach to combine haplotype analysis results. In
the first stage, each cohort estimate haplotype effect sizes in a regression framework, accounting for relatedness among
observations if appropriate. For the second stage, we use a multivariate generalized least square meta-analysis approach to
combine haplotype effect estimates from multiple cohorts. Haplotype-specific association tests and a global test of independence
between haplotypes and traits are obtained within our framework. We demonstrate through simulation studies that we control
the type-I error rate, and our approach is more powerful than inverse variance weighted meta-analysis of single SNV analysis
when haplotype effects are present. We replicate a published haplotype association between fasting glucose-associated locus
(G6PC2) and fasting glucose in seven studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology
Consortium and we provide more precise haplotype effect estimates.
Genet Epidemiol 40:244–252, 2016. © 2016 Wiley Periodicals, Inc.
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Introduction
In recent years, genome-wide association studies (GWAS)
have identified multiple common variants associated with
disease and disease-related traits. In a typical GWAS, associaThe copyright line for this article was changed on 5th May 2016 after original online
publication.
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tion between a trait and genetic variants is tested one variant
at a time, and variants with weak association routinely fail
to be detected, especially in small cohorts. Therefore, metaanalysis is often used by large consortia to increase statistical
power [Dupuis et al., 2010, Scott et al., 2012, Stram, 1996,
Zeggini et al., 2008] to detect variants with a moderate to
weak association with the trait of interest. Even with large
meta-analyses, variants identified to date only explain a small
proportion of the total heritability. In order to identify the
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source of the unexplained heritability, emerging approaches
have attempted to account for multiple variants at once when
evaluating association with a trait. Such approaches include
penalized regression methods [Li et al., 2011, Wu et al., 2009],
pathway analysis [Holden et al., 2008], gene-based tests such
as burden [Madsen and Browning, 2009] and SKAT [Wu et al.,
2010], and haplotype analysis [Liu et al., 2008, Schaid et al.,
2002, Tregouet et al., 2004]. The power of these approaches
can be enhanced by increasing sample size or combining multiple studies. Methods for meta-analysis of gene-based tests
are well established and widely used [Hu et al., 2013, Liu
et al., 2014], but there are no widely used methods for the
meta-analysis of haplotype association tests.
In this article, we propose a meta-analysis approach to
combine haplotype association results from multiple studies. In the first step of our method, each study provides
regression estimates and covariance matrices of haplotype
effects, with adjustment for familial correlation to accommodate familial samples or cryptic relatedness. In our second
step, cohort-specific haplotype effect estimates are pooled using a multivariate generalized least square meta-analysis approach. A global association test and evaluation of the effect
of each haplotype can be obtained within our framework.
We perform a simulation study to evaluate our approach,
comparing results with more traditional meta-analysis of
single-variant association tests and gene-based tests. Finally,
we replicate a published haplotype association between a
fasting glucose-associated locus (G6PC2) and fasting glucose
in seven studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium
and are able to provide more precise haplotype effect estimates than the prior report involving haplotype estimates
from a single cohort [Mahajan et al., 2015]. Code implementing the novel approach, along with a tutorial, is available at
http://sites.bu.edu/fhspl/publications/metahaplo.

Methods
Haplotype Association Test at Cohort Level
Our approach is based on Zaykin et al.’s [2002] haplotype analysis method for unrelated samples. We incorporate
random effects to account for family structure, making the
approach applicable to family-based cohorts, unrelated samples, or a mix of the two. We assume that a total of n subjects
from a study are sequenced in a region with q SNVs and as a
result, K haplotypes are observed. We assume a general linear
(mixed-effect) model, written as:
Y = Xα + β1 h1 + ... + βK hK + b + ,

(1)

where Y is an n × 1 quantitative trait vector, X is an n × p matrix of covariates (without intercept) including, for example,
age, sex, and associated genetic principal components controlling for potential population stratification, α is a p × 1
coefficient vector for the p adjustment variables, each n × 1
vector hm (m = 1, · · · , K ) is the expected haplotype dosage,
b is an n × 1 random effect vector that accounts for the relatedness within families, and  is an n × 1 vector of the ran-

dom error terms. When haplotype m of the j th (j = 1, · · · , n)
subject is observed, h mj , the j th entry in hm is either 0, 1, or 2,
that is, the number of copies of haplotype m the j th subject
carries. Otherwise, expected haplotype dosages E [h mj |Gj ]
are inferred from Gj , the q × 1 genotype vector of the j th
subject, using statistical algorithms such as the expectationmaximization (EM) algorithm [Dempster et al., 1977].
 =K For
the j th subject, the sum of the K haplotype dosages m
m=1 h mj
is always equal to 2. The n × 1 random effect vector b is assumed to follow a normal distribution N(0, σa2 ), where σa2
is the additive variance and  is the relationship matrix (with
entries equal to twice the kinship coefficient for related pairs
and 0 for unrelated pairs) derived from pedigree structure or
genome-wide information; in unrelated samples, the matrix
 reduces to I, the n × n identity matrix. Finally, we assume
the vector of error terms  follows a normal distribution
N(0, σe2 I), where σe2 is the variance of the error term.
Let Xo = (X, h1 , · · · , hK ) denote the overall design matrix
of size n × (p + K ), and define the overall variance matrix
as  = σa2  + σe2 I. The parameters α and βk (k = 1, · · · , K )
ˆ –1 Xo )–1 XoT 
ˆ –1 Y, where 
ˆ is evaluated
are estimated as (XoT 
at the maximum likelihood estimates σˆa2 and σˆe2 , which can
be obtained using the lmekin function in R’s coxme package
[Therneau, 2012]. The estimated variance of the effect estiˆ –1 Xo )–1 . The method reduces to an ordinary
mates is (XoT 
linear regression when applied to unrelated samples.
Meta-Analysis
We assume a total of N cohorts participate in the metaanalysis and the i-th (i = 1, · · · , N) cohort provides the estiˆ β̂i ) of the haplotype
mates β̂i and the covariance matrix var(
i
effects for K haplotypes, and a total of K  haplotypes are
observed in at least one cohort. We propose a multivariate meta-analysis approach [Becker and Wu, 2007] based on
generalized weighted least squares to combine the length K i
haplotype effect estimates from each cohort, denoted by β̂i
for studies i = 1, · · · , N, into a single effect estimate vector β̃
of length K  . The generalized weighted least square approach
is formulated as:
⎞
⎛
1 ... 0 ... 0
⎜0 ... ... ... 0⎟⎛ 1 ⎞
⎛ ˆ1 ⎞
⎟
⎜
β
⎜0 ... 0 ... 1⎟ β
⎟⎜
⎜
⎜ .. ⎟
⎟
β̂ = ⎝ . ⎠ = Wβ + e = ⎜ . . . . . ⎟ ⎝ ... ⎠ + e, (2)
⎜ .. .. .. .. .. ⎟

K
⎟
⎜
βˆN
⎝1 ... 0 ... 0⎠ β
0 ... 0 ... 1
where β̂i (i = 1, · · · , N) is the K i × 1 haplotype coefficient
vector for cohort i;
β̂ is the stacked haplotype coefficient vector from β̂i (i =
1, · · · , N);

β is the
⎛ K ×⎞1 coefficient vector of the haplotype effects;
W1

⎜ .. ⎟
W = ⎝ . ⎠ is a i K i × K  design matrix stacked from
WN
the N cohorts, where W i (i = 1, · · · , N) is a K i × K  matrix,
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with zeros and one in each row indicating which haplotype
effect is observed by cohort i;
e is the error term which is assumed to have a multivariate
normal distribution with a mean of 0 and a covariance matrix
of ⎛
⎞
var(βˆ1 ) · · ·
0
⎟
⎜
..
..
⎟
⎜
.
.
var(βˆk )
=⎜
⎟.
⎝ 0
ˆ
N
· · · var(β ) ⎠
Note that in the meta-analysis stage, cohort haplotypes are
reordered to match the order assigned to the K  haplotypes
observed in at least one cohort, and the design matrix W reflects this reordering. Furthermore, because  is unknown,
in our method, we substitute the sample estimate
⎛
⎞
ˆ βˆ1 ) · · ·
var(
0
⎜
⎟
..
..
⎟
ˆ βˆk )
.
.
var(
ˆ =⎜

⎜
⎟, hence the weighted least
⎝ 0
ˆ
N
ˆ β )⎠
· · · var(




ˆ W) W 
ˆ β̂ and
square estimator of β is β̃ = (W 
ˆ –1 W)–1 .
V = Var(β̃) = (W 
–1

–1

–1

Hypothesis Testing
The global null hypothesis of no association of any haplotype with the trait is expressed as
K

H0 : β = β = ... = β
1

2

(3)

To construct a test statistic to test for haplotype association, we reparameterize it into the equivalent null hypothesis,
where β1 is chosen from commonly observed haplotypes:
⎛ 1 ⎞ ⎛ 2 1 ⎞ ⎛ ⎞
γ
β –β
0
⎜ ..
⎟ ⎜ ..
⎟ ⎜ .. ⎟
H0 : γ = ⎝ .
(4)
⎠ = ⎝.
⎠ = ⎝. ⎠


γ K –1



βK – β1

0

The null hypothesis can be tested using a Wald test statistic
of the form
χ2 = γ̂ T [V∗ ]–1 γ̂,

(5)

where γ̂ is estimated from β̃ and V∗ is the covariance matrix
of γ̂, with a dimension of (K  – 1) × (K  – 1) and the jj  th
element having the form Vjj∗  = Vjj  – Vj 1 – Vj  1 + V11 . Under
the null hypothesis, the Wald test statistic follows a χ2K  –1 distribution asymptotically.

Table 1.

CHARGE cohorts

Cohort

Sample size
a

Generation Scotland: Scottish Family Health Study (GS)
Framingham Heart Studya (FHS)
Cardiovascular Health Study (CHS)
Family Heart Studya (FamHS)
Multi-Ethnic Study of Atherosclerosis (MESA)
FENLAND (FLD)
European Prospective Investigation into Cancer and
Nutrition, Potsdam (EPIC-Potsdam)
Total

7,678
6,561
3,525
3,393
2,507
1,341
300
25,305

a

Notes Family-based cohort.

Table 2.

Study designs for type-I error rate evaluation

Study No. of
design cohort
1
2
3
4
5
6
7
8
9

5
5
5
5
5
10
10
5
5

10

10

Sample sizes
250 NF2 (×5)
250 NFv (×5)
100 NF2, 175 NF2, 400 U, 700 U, 1000 U
100 NFv, 175 NFv, 400 U, 700 U, 1000 U
100 NFv, 175 NFv, 250 NFv, 325 NFv, 400 NFv
250 NF2 (×5); 1000 U (×5)
400 U, 700 U, 1000 U, 1300 U, 1600 U
100 NF2, 175 NF2, 250 NF2, 325 NF2, 400 NF2
250 NF2, 125 NF2 (×2), 375 NF2 (×2)
1000 U, 500 U (×2), 1500 U (×2)
250 NFv (×7), 1000 U (× 3)

Type-I
Type-I
error
error rate rate
(G6PC2) (JAZF1)
0.010
0.010
0.013
0.011
0.011
0.010
0.008
0.012
0.011

0.010
0.012
0.010
0.011
0.012
0.011
0.012
0.011
0.011

0.012

0.011

Notes NF2, nuclear family with 2 offspring; NFv, nuclear family with the number of
offspring randomly selected to be between 1 and 4; U, unrelated subjects.

diabetes, on the antidiabetic treatment of type-2 diabetes,
fasting plasma glucose ≥7 mmol/l, random plasma glucose
≥11.1 mmol/l, or hemoglobin A1C ≥ 6.5%. Study-specific
sample exclusions were detailed in [Wessel et al., 2015].
Genotypes were obtained from the Illumina HumanExome
BeadChip [Grove et al., 2013], a genotyping array containing 247,870 variants discovered through exome sequencing in
∼ 12,000 individuals, in which ∼ 75% of the variants are lowfrequency variants (Minor Allele Frequency (MAF) < 0.5%).
The main content of the chip comprises protein-altering variants (nonsynonymous coding, splice-site, and stop gain or
loss codons) seen at least three times in a study and in at
least two studies providing information to the chip design.
We selected four G6PC2 variants previously studied for their
haplotype association with fasting glucose [Mahajan et al.,
2015].

Cohorts for Heart and Aging Research in Genetic
Epidemiology Consortium

Simulation Studies

The CHARGE consortium comprises multiple studies with
the common goal of identifying genes and loci associated with
cardiovascular-related traits. Seven CHARGE cohorts contributed to a meta-analysis evaluating the association between
genetic variants and fasting glucose in 25,305 nondiabetic
participants (Table 1). Fasting glucose levels in millimole per
liter were analyzed in participants free of type-2 diabetes.
Type-2 diabetes was defined by cohorts referring to at least
one of the following criteria: a physician diagnosis of type-2

To evaluate the validity and power of our approach, we
perform a simulation study varying the number of cohorts
included in the meta-analysis (5 or 10), and the type of samples (unrelated, family-based, mix of the two). We also vary
the sample size from 400 up to 1,600 subjects per cohort.
See Table 2 for a description of the various study designs
investigated in type-I error rate and power.
Simulated trait values are dependent on sex, age, and
haplotypes/genetic variants (power evaluation only). Sex of

246

Genetic Epidemiology, Vol. 40, No. 3, 244–252, 2016

Table 3.

G6PC2 variants

Name
exm-rs560887
exm239664
exm239667
exm239672

Table 4.
rs560887

MapInfo

dbSNPID

Minor

Major

FHS MAF

2
2
2
2

169763148
169763262
169764141
169764176

rs560887
rs138726309
rs2232323
rs492594

A
T
C
C

G
C
A
G

0.293
0.0036
0.0078
0.4553

G6PC2 haplotype frequencies
rs138726309

rs2232323

rs492594

FHS frequency

C
C
C
C
T
C
T
C

A
A
A
C
A
A
A
C

C
G
G
G
C
C
G
G

0.46
0.29
0.24
0.006
< 0.001
< 0.001
< 0.001
< 0.001

C
T
C
T
C
T
C
C

Table 5.

Chr

JAZF1 variants (chromosome 7)

Name

Position

dbSNPID

Minor

Major

MAF

exm-rs10486567
exm2270592
exm-rs864745
exm-rs1635852
exm-rs849134

27976563
28039797
28180556
28189411
28196222

rs10486567
rs38523
rs864745
rs1635852
rs849134

A
C
G
C
G

G
T
A
T
A

0.2415
0.3683
0.4965
0.4973
0.4917

mothers and fathers (founders) are fixed in a heterosexual
marriage but are randomly assigned to offspring, with equal
probability. The age for unrelated individuals and the first
offspring in a family are generated from a uniform distribution over the range 30 to 50. Additional offspring’s ages are
set to be within 5 years of the first offspring with at least a 1
year gap (no twins), using a uniform distribution. For family
samples, the age of the mother is restricted to be 20–45 years
older than her offspring, and the father’s age to be within
5 years of the mother’s age, with a restriction that the age be
at least 20 years older than the older offspring.
We select the known T2D-associated genes G6PC2 (chromosome 2; Tables 3 and 4) and JAZF1 (chromosome 7;
Tables 5 and 6) to generate the reference panel haplotypes
(Tables 3 and 4). We use the observed haplotypes and frequencies estimated by EM algorithm from 6561 participants from the Framingham Heart Study. For example, in
JAZF1 no single haplotype has a frequency greater than
25% and eight haplotypes have frequency greater than 1%
(Table 6).
Genotypes are simulated by randomly assigning a pair of
haplotypes to founders, and by dropping randomly selected
haplotypes to offspring assuming no recombination within
haplotypes. Although phasing information is available in our
simulation setting, we do not use the phase information
when implementing our approach because such informa-

Table 6.

JAZF1 haplotype frequencies

Haplotype

rs10486567

rs38523

rs864745

rs1635852

rs849134

Frequency

G
G
G
G
A
A
A
A
A
A
A
G
G
G

T
T
C
C
T
T
C
C
T
T
C
T
T
C

A
G
G
A
A
G
A
G
G
A
A
A
G
G

T
C
C
T
T
C
T
C
T
C
C
C
T
T

A
G
G
A
A
G
A
G
A
A
A
A
A
A

0.2327
0.2295
0.1608
0.1295
0.0866
0.0793
0.0434
0.0259
0.0029
0.0029
0.0023
0.0019
0.0017
0.0005

1
2
3
4
5
6
7
8
9
10
11
12
13
14

tion is not typically available in real datasets. We use the EM
algorithm to infer expected haplotype dosage conditional on
genotypes via R package haplo.stats [Sinnwell and Schaid,
2013].
When estimating haplotype effects at the cohort-level, rare
haplotypes (frequency< 0.1%) are collapsed to stabilize the
computation and to avoid potential singularities due to high
LD among SNVs.
Type-I Error Rate
For evaluating the type-I error rate of our new approach,
a trait unassociated with the haplotypes is simulated using
a multivariate normal distribution with mean μ̂ = 0.02 ×
age + 0.5 × sex (sex is set to 1 for males and to 2 for females)
and a covariance matrix σa2  + σe2 I , with σa2 = σe2 = 0.5. Age
and sex explained about 10% and 5% of the trait variance,
respectively, resulting in a trait with moderate heritability
σa2
(h 2 = Var(Y)
≈ 0.42).
Cohort-specific analyses are performed by first estimating haplotypes using the EM algorithm implemented in the
R package haplo.stats, followed by regression analysis using
haplotype dosages and covariates as independent variables.
Cohort results are then meta-analyzed using the novel approach previously described, and the global association test
P values are recorded. Ten thousand simulations are performed to assess the type-I error rate in all scenarios at the
nominal threshold α = 0.01 (Table 2).
Power Evaluation
The power of our novel haplotype meta-analysis approach
is evaluated in a total of 16 scenarios (phenotype datasets) divided into four study designs (study design 1–4 from Table 2),
with varying haplotype or SNV effects. For each scenario, we
first compute the meta-analysis haplotype global test statistic,
and then compare to meta-analysis of both single variant tests
and gene-based tests. For single variant tests, we compute the
meta-analysis test statistic using inverse-variance weighted
method that has been shown to be the most powerful when
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Table 7.
rs560887

Single haplotype association test using 4SNVs on G6PC2 region
rs138726309

rs2232323

rs492594

C
C
C
C
T
C

A
A
A
C
A
A

C
G
G
G
C
C

C
T
C
T
C
T

β (SE)

P-value

Frequency

–0.073 (0.0055)

4.56 × 10–41
5.98 × 10–12
2.82 × 10–5
0.70
0.12

0.4394
0.2671
0.2645
0.0065
0.0021
0.0195

0.039 (0.0056)
–0.12 (0.029)
–0.022 (0.056)
–0.031 (0.020)

βM (SE M )a

–0.065(0.011)

0.034(0.012)
–0.205(0.057)
–0.202(0.077)

NA

Notes The haplotypes are observed in all cohorts except that the last one is observed only in FHS, CHS, GS, and FamHS.
a
βM and SE M denote the estimates from the paper of Mahajan et al. [2015].

the effect size is constant across cohorts [Zhou et al., 2011].
We then select the SNP with the minimum meta-analysis
P-value Pmin = min{1≤i≤K } Pi (K = 4 for G6PC2; K = 5 for
JAZF1) and adjust the meta-analysis P-value for multiple
testing using a Bonferroni correction for the effective number of independent variants [Gao et al., 2008]. We denote the
result for the best SNP in the single variant analysis by “min
P”. For gene-based tests, we choose SKAT and Burden test
with Wu weights and perform the analysis using R package
seqMeta [Voorman et al., 2014]. We use α = 0.001 to evaluate
the power of all four approaches.
For each scenario, the phenotype is simulated using a
multivariate normal distribution with mean μ̂ and a covariance matrix σa2  + σe2 I , with σa2 = σe2 = 0.5, but unlike
the type-I error scenarios, the value of μ̂ depends on genotypes/haplotypes in addition to the covariates of age and sex.
We investigate four genetic effect scenarios: one or two causal
genetic variants, or one or two causal haplotypes. For the
causal variant scenario, μ̂ = 0.02 × age + 0.5 × sex + bg 1 ×
g1 + bg 2 × g2 where gj (j = 1, 2) is a vector containing the
number of minor alleles (0, 1, or 2) carried by individuals in the sample, and bg j is the effect of variant j , set to
R2
,
4MAF j (1–MAF j )

where MAF j is the minor allele frequency

of variant j and R 2 = 0.01 is the proportion of variance
explained by this specific variant (haplotype). When only
one causal variant is√included in the model, bg 2 = 0 and
bg 1 is multiplied by 2. For the causal haplotype models,
μ̂ = 0.02 × age + 0.5 × sex + bh1 × h1 + bh2 × h2 , where h j
is a vector containing the number (conditional dosage) of
haplotype j carried by individuals in the sample, and bhj is
the effect of haplotype j , set to

R2
, where h̄ j
2h̄ j (1–h̄ j /2)
2

is mean

haplotype dosage of haplotype j and R = 0.01. When only
one causal haplotype
√ is included in the model, bh2 = 0 and bh1
is multiplied by 2. For the JAZF1 gene, we select two haplotypes, GTATA (the most frequent haplotype) and GCGCG
(the third most frequent haplotype), to have an effect on the
phenotype while all other haplotypes have no effect on the
phenotype. For models with single variant effects, we select
rs849134 and rs38523 to have nonzero effect on the trait,
while all other genetic variants have no effect. For the G6PC2
gene, we select CCAC and TCAG, the two most frequent haplotypes to have an effect on the phenotype. For models with
single variant effects, we select rs560887 and rs2232323 to
have nonzero effect on the trait.

248

Genetic Epidemiology, Vol. 40, No. 3, 244–252, 2016

A thousand simulations with five independent cohorts are
performed to compare the power of our approach to the single
variant method adjusted for multiple testing and gene-based
methods.

Results
Meta-Analysis of Four Coding Variants on G6PC2 Region
G6PC2 is a known locus to affect fasting glucose level.
Among the 17 exonic variants on the exome chip, 15 are rare
variants (MAF<1%) and two are common variants (rs560887
with MAF = 25.4%; rs492594 with MAF = 43.7%). Previous
GWAS have identified the A allele of rs560887, one of the two
common variants to be associated with lower fasting glucose level ([Bouatia-Naji et al., 2008]: β = –0.07 mmol/l, p =
6 × 10–16 ; [Dupuis et al., 2010]: β = 0.075 ± 0.003 mmol/l,
p = 8.5 × 10–122 ). A recent large-scale exome-chip analysis
indicated that these 15 rare variants also had a joint effect on
fasting glucose [Wessel et al., 2015]. Our approach is applied
to study the association between the haplotype structure of
four coding variants rs560887, rs138726309, rs2232323, and
rs492594 and fasting glucose, using CHARGE exome-chip
data. We perform a meta-analysis of seven studies comprising of three family-based and four population-based cohorts
with up to 25,305 non-diabetic European participants, to better understand how the overall haplotype structure as well as
how the single haplotype affect fasting glucose level. With
a meta-analysis sample size of 25,305, we have successfully
replicated a previous reported haplotype analysis of four coding variants on G6PC2 region [Mahajan et al., 2015], but with
higher precision (Table 7). Our effect size estimates are consistent with previously published estimates, in terms of both
direction and magnitude. However, prior results were based
on a single population-based cohort with 4,442 participants.
In contrast, our analysis is based on seven cohorts with over
25,000 participants. Among the five haplotypes shared by all
seven studies, one copy of the most significant haplotype,
TCAG, decreases fasting glucose levels by 0.074 (95% confidence interval (CI): 0.063,0.085) mmol/l, on average; one
copy of the second most significant haplotype, CCAG, increases the average fasting glucose levels by 0.039 (95% CI:
0.028,0.050) mmol/l; and one copy of the third most significant haplotype, TCCG, decreases fasting glucose levels
by an average of 0.12 (95% CI: 0.065,0.18) mmol/l. Most

Figure 1. Power of the haplotype meta-analysis approach compared to gene-based methods and single SNV meta-analysis (min P) adjusted for
multiple testing in the G6PC2 region, evaluated at α = 0.001 in four study designs. Description of the four study designs used in the simulation can
be found in Table 2 (study design 1–4). The labels on the x axes denote that 1 (SNV) or 2 (2SNVs) SNVs are influencing the phenotypes, or 1 (1HAP)
or 2 (2HAPs) haplotypes have an effect on the phenotypes.

haplotype effect estimates reported in Mahajan et al. [2015]
fall within our 95 % CI, with the exception of estimates for
TCCG (Mahajan et al.’s [2015] estimates = 0.205), which fall
just outside our reported CI.

study designs (Figures 1 and 2) because of the Wu (default)
weighing scheme that downweights common variants.

Discussion
Simulations
Ten scenarios with increasing diversity in the study designs
of the cohorts included in the meta-analysis are simulated to
evaluate type-I error rate of our approach. The type-1 error
rate is well controlled in all scenarios investigated (Table 2).
In the simulations to evaluate power, our approach is
shown to be almost as powerful as the single SNV approach
when SNVs are influencing the trait, but much more powerful to detect true haplotype effects. For example, in the family
based design scenarios, our approach is 40% more powerful
than single SNV analyses when two haplotypes have nonzero
effect on the phenotypes (Figures 1 and 2). A similar pattern
is observed for designs with a mix of unrelated and related
samples. The gain in power is smaller when a single haplotype is influencing the trait, but present for all scenarios
evaluated. When compared to the gene-based tests, our approach is uniformly more powerful in all scenarios across all

We have proposed a general meta-analysis approach to
combine the haplotype association results from multiple cohorts. Our approach imposes no restrictions on the haplotypes observed across cohorts. Instead, our approach can
incorporate information from haplotypes observed in a single cohort in addition to haplotypes observed in multiple
cohorts. In the first stage of our approach, haplotype association analysis is performed at the cohort level. Information
about the haplotype structure, frequencies, effect estimates,
and covariance of effect estimates is collected, and metaanalyzed in the second stage using a generalized weighted
least square approach. The association between a trait and
any single or multiple haplotypes can be easily evaluated
within our framework.
We evaluated the type-I error rate in a variety of scenarios
with different cohort designs that included a mix of unrelated and family samples. Type-I error rate was controlled
in all scenarios investigated. We also compared the power of
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Figure 2. Power of the haplotype meta-analysis approach compared to gene-based methods and single SNV meta-analysis (min P) adjusted for
multiple testing in the JAZF1 region, evaluated at α = 0.001 in four study designs. Description of the four study designs used in the simulation can
be found in Table 2 (study design 1–4). The labels on the x axes denote that 1 (SNV) or 2 (2SNVs) SNVs are influencing the phenotypes, or 1 (1HAP)
or 2 (2HAPs) haplotypes have an effect on the phenotypes.

our approach with single variant tests corrected for multiple
testing (min P approach), and demonstrated that our approach had equivalent power when variants, not haplotypes,
influenced the trait, but was more powerful in the presence
of true haplotype effects. Our haplotype approach also provided more evidence for association compared to gene-based
tests applied with the default weighting scheme, as exemplified in a recent large-scale exome-chip project [Wessel
et al., 2015] applied to the G6PC2 region comprising 15
rare variants (MAF<1%). Our simulations also illustrated
that the haplotype effect size estimates obtained from metaanalysis were unbiased, even when family-based cohorts were
included.
While our approach cannot serve as the only tool for the
discovery of associated variants and regions, it is a complementary tool to single-variant and gene-based tests. Mahajan
et al. [2015] demonstrated the usefulness of haplotype analysis in their investigation of the effect of G6PC2 variants on
fasting glucose. In 4,442 nondiabetic subjects from the Oxford Biobank, the G allele from the coding variant rs492594
appears to significantly decrease fasting glucose levels. However, when conditioning on the variant with the largest effect
(rs560887) on fasting glucose, the effect estimates of the G-
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allele from rs492594 is reversed, and the G allele appears
to decrease fasting glucose, an apparent paradox. However,
looking at the haplotype estimates elucidates the mystery: the
rs492594 G allele is most frequently observed on the same
haplotype as the glucose raising allele (T) from the strongest
associated variant (rs560887), giving the impression that the
G allele also increases fasting glucose. Our analysis supports
this conclusion, and refines the effect estimates provided by
Mahajan et al. [2015] by increasing the number of samples
used to obtain effect estimates via meta-analysis, providing
more precise estimates, as reflected in the smaller standard
errors.
Our approach has some limitations. The variants included
in the haplotype analysis must be genotyped or imputed in all
cohorts. In other words, all cohorts must include the same set
of variants in their analysis. Moreover, when using imputed
genotypes, best-guess genotypes must be used because the
approach does not currently handle genotypes in the form of
dosage. The EM algorithm currently employed for inferring
haplotypes works best for a moderate number of variants
(< 15), and very rare haplotypes (frequency< 0.1%) are recommended to be collapsed to ensure computation stability.
Despite these limitations, our approach has the potential to

shed some light on the relationship between traits and multiple associated SNVs in a region.
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